🔗 Share this article

As the United States continues making sweeping changes to its vaccination guidelines, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines during the global health crisis and has concentrated on possible deaths after Covid immunization in her recent position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Program

Agency leaders were set to announce major changes to the pediatric vaccine schedule recently, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would put the US out of step with a large portion of the international standard with little proof for improved outcomes. This reveal has been postponed until the coming year.

In place of the top vaccines chief, Høeg is set to speak at the meeting. She was recently named interim head of the FDA’s CDER, the fifth person to run the office this year.

A New Direction at the Agency

The acting appointment may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the FDA – and it signals a renewed priority upon rolling back previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing some pediatric shot schedules in the US so as to align more in line with the Danish model, a country with universal health coverage and a population roughly the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccines – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Expertise

Høeg has no obvious experience in pharmaceutical research, oversight or administrative roles, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a large organization. She is not an expert in drug approvals.”

Previous heads of the center would “grasp legal statutes and the underlying principles of medication creation”, commented Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who headed CBER have had.”

This division has an immense workload at the agency, she stated.

“The public just zeroes in on the novel medication approvals, but the generic drug division clears thousands of generic medications. There is also a biosimilars program, OTC medication office and other areas, and all of those must be looked after,” Woodcock noted. “The area you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a major administrative component to the role, which supervises over 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” Woodcock concluded.

Official Statement and Disputed Programs

In response to concerns about Dr. Høeg's qualifications and whether this selection indicates more teamwork among agency officials on vaccines, a press secretary said that the “concerns stem from flawed presumptions”.

“Her resume is consistent with the responsibilities of her role,” the official explained, pointing to the period Høeg spent counseling the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed expedited drug-approval program that reportedly concerned her preceding directors. “How are these therapies being picked for this voucher program? Who makes the decisions?” Dr. Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he remarked, “the FDA seems to be moving towards less stringent regulations of pharmaceuticals, with the exception of immunizations.”

Established History on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if troubling, past, Howard have noted. She published a study using unconfirmed crowd-sourced reports to determine the incidence of myocarditis after Covid vaccination. She counseled the Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the current federal leadership included revising regulations for new vaccines and ending “non-essential” immunizations, she remarked following the vote on a audio program. At the agency, Høeg has reportedly suggested barring adolescent males from obtaining COVID-19 vaccines.

“She is an thorough ideologue who commences with her conclusions and tailors the evidence to accommodate the data in a extremely misleading, fraudulent manner,” Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|